Dr. John C. Henegan
Claim this profileUniversity of Mississippi Medical Center
Studies Prostate Cancer
Studies Bladder Cancer
18 reported clinical trials
65 drugs studied
About John C. Henegan
Education:
- Obtained MD from the University of Mississippi School of Medicine in 2007.
- Completed Residency in Internal Medicine at the University of Mississippi Medical Center in 2010.
- Finished Fellowship in Pulmonary and Critical Care Medicine at the same institution in 2013.
Experience:
- Currently serves as an Assistant Professor of Medicine in the Division of Pulmonary, Critical Care, and Sleep Medicine at the University of Mississippi Medical Center.
Area of expertise
1Prostate Cancer
Stage IV
TP53 positive
TP53 negative
2Bladder Cancer
Stage IV
Stage III
Stage I
Affiliated Hospitals
Clinical Trials John C. Henegan is currently running
Eribulin + Chemotherapy
for Bladder Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3
Carboplatin + Cabazitaxel
for Prostate Cancer
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels (castrate-resistant) and that has spread from where it first started (primary site) to other places in the body (metastatic). Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Chemotherapy drugs, such as cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Prednisone is often given together with chemotherapy drugs. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs and to help the chemotherapy work. Giving carboplatin with the standard of care chemotherapy drug cabazitaxel may be better at treating metastatic castrate-resistant prostate cancer.
Recruiting2 awards Phase 35 criteria
More about John C. Henegan
Clinical Trial Related4 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments John C. Henegan has experience with
- Nivolumab
- Docetaxel
- Flutamide
- Prednisone
- Goserelin Acetate
- Nilutamide
Breakdown of trials John C. Henegan has run
Prostate Cancer
Bladder Cancer
Prostate Adenocarcinoma
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John C. Henegan specialize in?
John C. Henegan focuses on Prostate Cancer and Bladder Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are TP53 positive.
Is John C. Henegan currently recruiting for clinical trials?
Yes, John C. Henegan is currently recruiting for 7 clinical trials in Jackson Mississippi. If you're interested in participating, you should apply.
Are there any treatments that John C. Henegan has studied deeply?
Yes, John C. Henegan has studied treatments such as Nivolumab, Docetaxel, Flutamide.
What is the best way to schedule an appointment with John C. Henegan?
Apply for one of the trials that John C. Henegan is conducting.
What is the office address of John C. Henegan?
The office of John C. Henegan is located at: University of Mississippi Medical Center, Jackson, Mississippi 39216 United States. This is the address for their practice at the University of Mississippi Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.